Inceptua - Pharma Company and Service Partner
@InceptuaGroup
Followers
380
Following
226
Media
29
Statuses
234
We bring medicines to patients through clinical trial distribution services, pre-approval and unlicensed medicines access, and commercialization of products.
Operations across US, EU, Asia
Joined May 2017
We often get questions about #PreApproval access #EarlyAccess #ManagedAccess #CompassionateUse #NamedPatientProgram) and #UnlicensedMedicines. Follow the link read to read our Q&A with @StuartBMAC, @InceptuaGroup: https://t.co/LheBmQk9TB
#pharmaindustry #biotech #drugs
0
1
1
Don't forget to register for the free webinar on Monday the 14th of December with expert speakers from @pfizer and Inceptua on Strategic #ComparatorSourcing in #China. #chinesemarket #pharma #clinicalsupply. https://t.co/cPp8Fd7HLn
xtalks.com
China is now the second-largest pharmaceutical market in the world, and with a more harmonized and efficient clinical trial approval process, it is seeing a large increase in clinical trial activity...
0
0
1
How to optimize your oncology clinical trial supply? Learn more here: https://t.co/elhL0vvsuA
#oncology #clinicaltrials #comparatorsourcing #pharma #biotech #CRO
0
0
0
Jeremy Broadis and @ME_Corbett are attending #bioeurope digital, October 26-29. Don't hesitate to reach out and get in touch to discuss launch partnerships for Europe or global pre-approval access #partnerships #specialtycare #rarediseases #earlyaccess
0
0
0
@InceptuaGroup receives approval of marketing authorization transfer of Jetrea® (ocriplasmin) for the treatment of symptomatic vitreomacular adhesion https://t.co/AMHyYMFGYB
#Jetrea #vitreolysis #treatment #EC
0
1
2
Inceptua participated in an initiative to raise awareness of the challenges of access to treatment for patients suffering from #rarediseases: https://t.co/3snPdBXiPn. Don't hesitate to connect with @StuartBMAC and reach out with any questions you may have. #earlyaccess
healthawareness.co.uk
Across Europe there is disparity in the average time for new drugs to be approved and accessible to patients. There are a number of factors delaying these processes. Drugs are approved in Europe,...
0
0
1
0
0
1
0
0
2
Access our latest webinar #ondemand
https://t.co/6kl42nuWdz and learn more about #ExpandedAccess as a Key Component in the #Drugdevelopment and #Launch Process #preapprovalaccess
0
0
2
We anticipate three key trends for #comparatorsourcing in #China: 1. continued action against low quality and counterfeited products, 2. improved quality of local generics, and 3. a focus on lower costs. Learn more by following the link, and go to page 68: https://t.co/VcipXAx6nq
0
0
0
Welcome the more than 280 people across the industry who have already registered to join our webinar, February 20 (3PM London/10AM New York), on #expanded access as a key component in the development and launch process. You still have the chance to join: https://t.co/O7rgjjZ6Jo
0
1
4
LUXEMBOURG / SAN FRANCISCO – 7th February 2020 – Inceptua and @portola_pharma have entered into an agreement whereby Inceptua will become Portola’s exclusive distribution partner for Ondexxya® in selected countries: https://t.co/VJh5etEJwk
1
0
1
Welcome to our new Head of Asia Pacific, #clinicaltrial Services, Philip Gregory. Read the full press release here: https://t.co/W4dM5P1A8l
0
0
2
Thanks to everyone attending the @Expanded_Access Summit and the session on 'The Integration of #EarlyAccess into Treatment and Clinical Research' with Inceptua’s @StuartBMAC. Don't miss our free webinar, February 20 Click here to register: https://t.co/g6T2K9l1is
0
0
1
0
0
0
"Across #rarediseases (...) we share the same goal: Getting treatments to patients in need (...). In Europe it can take up to 1100 days for an #orphandrug to become available (...) Make treatment available faster through pre-approval access (...)." @ME_Corbett, #WODC2019.
0
1
0
Welcoming back the incomparable Stuart Bell, PhD to discuss the latest innovation in pragmatic trial design for #ExpandedAccess Jan. 27-29, 2020 https://t.co/LyxIWz0Gyc
0
1
2
Jeremy Broadis and Sarah Fry are attending #BIO2019 in Philadelphia to discuss how we can help get rare disease therapies to patients in need. DM us if you’d like to discuss opportunities further. #medicinesaccess #preapproval #orphandrugs #helpingpharmahelpingpatients #pharma
0
0
1
Brilliant @JAMAOnc paper on single patient use #expandedaccess at @mskcc by Hyman et. al. 36.1% of products were in Phase 2, 39.4% in Phase 3, and an incredible 18.8% were in Phase 1. Authors call for routine prospective collection of efficacy data in expanded access. Fully agree
0
8
10